avkАрхивъ внутренней медициныThe Russian Archives of Internal Medicine2226-67042411-6564“SINAPS” LLC10.20514/2226-6704-2020-10-4-314-321avk-1077Research ArticleРАЗБОР КЛИНИЧЕСКИХ СЛУЧАЕВANALYSIS OF CLINICAL CASESСлучай острой стероид-индуцированной миопатии у пациентки с аутоиммунной тромбоцитопенией (клинический слу чай)The Case of Acute Steroid-Induced Myopathy in the Patient with Autoimmune ThrombocytopeniaВатутинН. Т.VatutinN. T.

Донецк

Donetsk

ИгнатенкоГ. А.IgnatenkoG. A.

Донецк

Donetsk

https://orcid.org/0000-0003-3984-8482ТарадинГ. Г.TaradinG. G.

Донецк

Donetsk

taradin@inbox.ruКанишеваИ. В.KanishevaI. V.

Донецк

Donetsk

ШаймурзинМ. Р.ShajmurzinM. R.

Донецк

Donetsk

ГОО ВПО «Донецкий национальный медицинский университет им. М. Горького»; ГУ «Институт неотложной и восстановительной хирургии им. В.К. Гусака»РоссияState Educational Organization of Higher Professional Education «M. Gorky Donetsk National Medical University»; State Institution «V.K. Gusak Institute of Urgent and Recovery Surgery»Russian FederationГОО ВПО «Донецкий национальный медицинский университет им. М. Горького»РоссияState Educational Organization of Higher Professional Education «M. Gorky Donetsk National Medical University»Russian FederationРеспубликанский клинический центр нейрореабилитацииРоссияHospital of Republican Clinical Centre for NeurorehabilitationRussian Federation202030072020104314321Copyright © Ватутин Н.Т., Игнатенко Г.А., Тарадин Г.Г., Канишева И.В., Шаймурзин М.Р., 20202020Ватутин Н.Т., Игнатенко Г.А., Тарадин Г.Г., Канишева И.В., Шаймурзин М.Р.Vatutin N.T., Ignatenko G.A., Taradin G.G., Kanisheva I.V., Shajmurzin M.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medarhive.ru/jour/article/view/1077

Статья посвящена одному из частых побочных эффектов терапии глюкокортикоидов — стероидной миопатии. Приводятся сведения о патогенетич еских особенностях развития миопатии при применении глюкокортикоидов, описываются наиболее типичные клинические проявления, а также результаты диагностических методов с оценкой роли измерения уровней ферментов, электромиографии, ультразвукового исследования мышечной ткани, компьютерной и магнитно-резонансной томографии. Приводится описание развития мышечной слабости у 49-летней больной, которой в связи с выявленной первичной иммунной тромбоцитопенией был назначен метилпреднизолон в суточной дозировке 88 мг. Через неделю терапии больная начала отмечать появление и нарастание мышечной слабости, ограничивающей движение и самообслуживание. После ряда выполненных исследований и, в частности, электромиографии, был предположен стероидный генез миопатии. После отмены глюкокортикоидов и назначения препаратов кальция, витамина D и анаболических средств, состояние больной стало улучшаться, и она была выписана из клиники.

The article concerns one of the common adverse effects during treatment — steroid myopathy. The information about pathogenic specifics of myopathy development in administration of glucocorticoids, the most typical clinical manifestations are described, and results diagnostic methods with estimation of a role of enzyme level evaluation, electromyography, ultrasound study of the muscle tissue, computer and magnetic resonance tomography. There is description of muscle weakness development in 49-year old woman who has been receiving methylprednisolone 88 mg/day due to revealed thrombocytopenia. One week after the treatment was started the patient experienced onset and progression of muscle weakness limiting her motion and self-maintenance. After performing of investigation including electromyography steroid genesis of myopathy was suggested. The patient’s condition began to improve after disc ontinuation of glucocorticoids and administration of calcium supplements, vitamin D, and anabolics, and the patient was discharged.

тромбоцитопенияметилпреднизолонглюкокортикоидыпобочные эффектыстероидная миопатиялечениеthrombocytopeniamethylprednisoloneglucocorticoidsadverse effectssteroid myopathytreatmentReferencesCushing H. The basophil adenoma of the pituitary body and their clinical manifestation. J Neurosurg. 1932; 21(4): 318-47. doi: 10.3171/jns.1964.21.4.0318.Cushing H. The basophil adenoma of the pituitary body and their clinical manifestation. J Neurosurg. 1932; 21(4): 318-47. doi: 10.3171/jns.1964.21.4.0318.Pivonello R., Isidori A.M., De Martino M.C., et al. Complications of Cushing’s syndrome: state of the art. Lancet Diabetes Endocrinol. 2016; 4(7): 611-29. doi: 10.1016/S2213-8587(16)00086-3.Pivonello R., Isidori A.M., De Martino M.C., et al. Complications of Cushing’s syndrome: state of the art. Lancet Diabetes Endocrinol. 2016; 4(7): 611-29. doi: 10.1016/S2213-8587(16)00086-3.Gupta A, Gupta Y. Glucocorticoid-induced myopathy: Pathophysiology, diagnosis, and treatment. Indian J Endocrinol Metab. 2013; 17(5): 913-6. doi: 10.4103/2230-8210.117215.Gupta A, Gupta Y. Glucocorticoid-induced myopathy: Pathophysiology, diagnosis, and treatment. Indian J Endocrinol Metab. 2013; 17(5): 913-6. doi: 10.4103/2230-8210.117215.Owczarek .J, Jasińska M., Orszulak-Michalak D. Drug-induced myopathies. An overview of the possible mechanisms. Pharmacol Rep. 2005 ;57(1): 23-34. PMID: 15849374.Owczarek .J, Jasińska M., Orszulak-Michalak D. Drug-induced myopathies. An overview of the possible mechanisms. Pharmacol Rep. 2005 ;57(1): 23-34. PMID: 15849374.Schakman O, Kalista S., Barbé C., et al. Glucocorticoidinduced skeletal muscle atrophy. Int J Biochem Cell Biol. 2013; 45(10): 2163-72. doi: 10.1016/j.biocel.2013.05.036.Schakman O, Kalista S., Barbé C., et al. Glucocorticoidinduced skeletal muscle atrophy. Int J Biochem Cell Biol. 2013; 45(10): 2163-72. doi: 10.1016/j.biocel.2013.05.036.Kostyo J.L., Redmond A.F. Role of protein synthesis in the inhibitory action of adrenal steroid hormones on amino acid transport by muscle. Endocrinology. 1966; 79(3): 531–40. doi: 10.1210/endo-79-3-531.Kostyo J.L., Redmond A.F. Role of protein synthesis in the inhibitory action of adrenal steroid hormones on amino acid transport by muscle. Endocrinology. 1966; 79(3): 531–40. doi: 10.1210/endo-79-3-531.Liu Z., Li G., Kimball S.R., et al. Glucocorticoids modulate amino acid-induced translation initiation in human skeletal muscle. Am J Physiol Endocrinol Metab. 2004; 287(2): E275–81. doi: 10.1152/ ajpendo.00457.Liu Z., Li G., Kimball S.R., et al. Glucocorticoids modulate amino acid-induced translation initiation in human skeletal muscle. Am J Physiol Endocrinol Metab. 2004; 287(2): E275–81. doi: 10.1152/ ajpendo.00457.Hasselgren P.O. Glucocorticoids and muscle catabolism. Curr Opin Clin Nutr Metab Care. 1999; 2(3): 201–5. doi: 10.1097/00075197199905000-00002.Hasselgren P.O. Glucocorticoids and muscle catabolism. Curr Opin Clin Nutr Metab Care. 1999; 2(3): 201–5. doi: 10.1097/00075197199905000-00002.Tiao G., Fagan J., Roegner V., et al. Energyubiquitindependent muscle proteolysis during sepsis in rats is regulated by glucocorticoids. JCI Insight. 1996; 97(2): 339–48. doi: 10.1172/JCI118421.Tiao G., Fagan J., Roegner V., et al. Energyubiquitindependent muscle proteolysis during sepsis in rats is regulated by glucocorticoids. JCI Insight. 1996; 97(2): 339–48. doi: 10.1172/JCI118421.Bodine S.C., Latres E., Baumhueter S., et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 2001; 294(5547): 1704–8. doi: 10.1126/science.1065874.Bodine S.C., Latres E., Baumhueter S., et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 2001; 294(5547): 1704–8. doi: 10.1126/science.1065874.Mitch W.E., Goldberg A.L. Mechanisms of muscle wasting. The role of the ubiquitinproteasome pathway. New Engl J Med. 1996; 335(25): 1897–905. doi: 10.1056/NEJM199612193352507.Mitch W.E., Goldberg A.L. Mechanisms of muscle wasting. The role of the ubiquitinproteasome pathway. New Engl J Med. 1996; 335(25): 1897–905. doi: 10.1056/NEJM199612193352507.Combaret L., Adegoke O.A., Bedard N., et al. USP19 is a ubiquitinspecific protease regulated in rat skeletal muscle during catabolic states. Am J Physiol Endocrinol Metab. 2005; 288(4): E693–700. doi: 10.1152/ajpendo.00281.2004.Combaret L., Adegoke O.A., Bedard N., et al. USP19 is a ubiquitinspecific protease regulated in rat skeletal muscle during catabolic states. Am J Physiol Endocrinol Metab. 2005; 288(4): E693–700. doi: 10.1152/ajpendo.00281.2004.Sacheck J.M., Ohtsuka A., McLary S.C., et al. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am J Physiol Endocrinol Metab. 2004; 287(4): E591–601. doi: 10.1152/ ajpendo.00073.2004.Sacheck J.M., Ohtsuka A., McLary S.C., et al. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am J Physiol Endocrinol Metab. 2004; 287(4): E591–601. doi: 10.1152/ ajpendo.00073.2004.Yamamoto D., Maki T., Herningtyas E.H., et al. Branched-chain amino acids protect against dexamethasone-induced soleus muscle atrophy in rats. Muscle Nerve. 2010; 41(6): 819-27. doi: 10.1002/mus.21621.Yamamoto D., Maki T., Herningtyas E.H., et al. Branched-chain amino acids protect against dexamethasone-induced soleus muscle atrophy in rats. Muscle Nerve. 2010; 41(6): 819-27. doi: 10.1002/mus.21621.Wang X.H., Zhang L., Mitch W.E., et al. Caspase-3 cleaves specific 19 S proteasome subunits in skeletal muscle stimulating proteasome activity. J Biol Chem. 2010; 285(28): 21249–57. doi: 10.1074/jbc.M109.041707.Wang X.H., Zhang L., Mitch W.E., et al. Caspase-3 cleaves specific 19 S proteasome subunits in skeletal muscle stimulating proteasome activity. J Biol Chem. 2010; 285(28): 21249–57. doi: 10.1074/jbc.M109.041707.Büyükcam F., Calık M., Erkuran M.K., et al. Hypokalemia and muscle paralysis after low-dose methylprednisolone. Am J Emerg Med. 2011; 29(5): 573.e1-2. doi: 10.1016/j.ajem.2010.05.00.Büyükcam F., Calık M., Erkuran M.K., et al. Hypokalemia and muscle paralysis after low-dose methylprednisolone. Am J Emerg Med. 2011; 29(5): 573.e1-2. doi: 10.1016/j.ajem.2010.05.00.Fournier M., Huang Z.S., Li H., et al. Insulin-like growth factor-I prevents corticosteroid-induced diaphragm muscle atrophy in emphysematous hamsters. Am J Physiol Regul Integr Comp Physiol. 2003; 285(1): R34–43. doi: 10.1152/ajpregu.00177.2002.Fournier M., Huang Z.S., Li H., et al. Insulin-like growth factor-I prevents corticosteroid-induced diaphragm muscle atrophy in emphysematous hamsters. Am J Physiol Regul Integr Comp Physiol. 2003; 285(1): R34–43. doi: 10.1152/ajpregu.00177.2002.Shimizu N., Yoshikawa N., Ito N., et al. Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metabolism. 2011; 13(2): 170–82. doi: 10.1016/j. cmet.2011.01.001.Shimizu N., Yoshikawa N., Ito N., et al. Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metabolism. 2011; 13(2): 170–82. doi: 10.1016/j. cmet.2011.01.001.Pereira R.M., Freire de Carvalho J. Glucocorticoid-induced myopathy. Joint Bone Spine. 2011; 78(1): 41-4. doi: 10.1016/j. jbspin.2010.02.025Pereira R.M., Freire de Carvalho J. Glucocorticoid-induced myopathy. Joint Bone Spine. 2011; 78(1): 41-4. doi: 10.1016/j. jbspin.2010.02.025Полунина А.Г., Исаев Ф.В., Демьянова М.А. Стероидная миопатия (обзор). Журнал неврологии и психиатрии им. С.С. Корсакова. 2012; 10(2): 60-64. PMID: 23250613.Polunina A.G., Isaev F.V., Demyanova M.A. S.S. Korsakov Journal of Neurology and Psychiatry. 2012; 10(2): 60-64 [In Russian].Miller M.L. Glucocorticoid-induced myopathy. Indian J Endocrinol Metab. 2013; 17(5): 913-6. doi: 10.4103/2230-8210.117215.Miller M.L. Glucocorticoid-induced myopathy. Indian J Endocrinol Metab. 2013; 17(5): 913-6. doi: 10.4103/2230-8210.117215.Minetto M.A., Rainoldi A., Jabre J.F. The clinical use of macro and surface electromyography in diagnosis and follow-up of endocrine and drug-induced myopathies. J. Endocrinol. Invest. 2007; 30(9): 791-6. doi: 10.1007/BF03350820.Minetto M.A., Rainoldi A., Jabre J.F. The clinical use of macro and surface electromyography in diagnosis and follow-up of endocrine and drug-induced myopathies. J. Endocrinol. Invest. 2007; 30(9): 791-6. doi: 10.1007/BF03350820.Minetto M.A., D’Angelo V., Arvat E., et al. Diagnostic work-up in steroid myopathy. Endocrine. 2018; 60(2): 219-23. doi: 10.1007/ s12020-017-1472-5.Minetto M.A., D’Angelo V., Arvat E., et al. Diagnostic work-up in steroid myopathy. Endocrine. 2018; 60(2): 219-23. doi: 10.1007/ s12020-017-1472-5.Maffiuletti N.A. Assessment of hip and knee muscle function in orthopaedic practice and research. J. Bone Joint Surg. Am. 2010; 92(1): 220–9. doi: 10.2106/JBJS.I.00305.Maffiuletti N.A. Assessment of hip and knee muscle function in orthopaedic practice and research. J. Bone Joint Surg. Am. 2010; 92(1): 220–9. doi: 10.2106/JBJS.I.00305.Bohannon R.W. Measuring knee extensor muscle strength. Am. J. Phys. Med. Rehabil. 2001; 80(1): 13-8. doi: 10.1097/00002060200101000-00004.Bohannon R.W. Measuring knee extensor muscle strength. Am. J. Phys. Med. Rehabil. 2001; 80(1): 13-8. doi: 10.1097/00002060200101000-00004.Baudry S., Lanfranco F., Merletti R., et al. Effects of short-term dexamethasone administration on corticospinal excitability. Med. Sci. Sports Exerc. 2014; 46(4): 695–701. doi: 10.1249/ MSS.0000000000000162.Baudry S., Lanfranco F., Merletti R., et al. Effects of short-term dexamethasone administration on corticospinal excitability. Med. Sci. Sports Exerc. 2014; 46(4): 695–701. doi: 10.1249/ MSS.0000000000000162.Khaleeli A.A., Edwards R.H., Gohil K., et al. Corticosteroid myopathy: a clinical and pathological study. Clin Endocrinol (Oxf). 1983; 18(2): 155-66. doi: 10.1111/j.1365-2265.1983.tb03198.Khaleeli A.A., Edwards R.H., Gohil K., et al. Corticosteroid myopathy: a clinical and pathological study. Clin Endocrinol (Oxf). 1983; 18(2): 155-66. doi: 10.1111/j.1365-2265.1983.tb03198.Lovitt S., Marden F.A., Gundogdu B., et al. MRI in myopathy. Neurol. Clin. 2004; 22(3): 509–538. doi: 10.1016/j. ncl.2004.03.008.Lovitt S., Marden F.A., Gundogdu B., et al. MRI in myopathy. Neurol. Clin. 2004; 22(3): 509–538. doi: 10.1016/j. ncl.2004.03.008.Zoico E., Corzato F., Bambace C., et al. Myosteatosis and myofibrosis: relationship with aging, inflammation and insulin resistance. Arch. Gerontol. Geriatr. 2013; 57(3): 411–6. doi: 10.1016/j.archger.2013.06.001.Zoico E., Corzato F., Bambace C., et al. Myosteatosis and myofibrosis: relationship with aging, inflammation and insulin resistance. Arch. Gerontol. Geriatr. 2013; 57(3): 411–6. doi: 10.1016/j.archger.2013.06.001.Lee K., Shin Y., Huh J., et al. Recent issues on body composition imaging for sarcopenia evaluation. Korean J Radiol. 2019; 20(2): 205-17. doi: 10.3348/kjr.2018.0479.Lee K., Shin Y., Huh J., et al. Recent issues on body composition imaging for sarcopenia evaluation. Korean J Radiol. 2019; 20(2): 205-17. doi: 10.3348/kjr.2018.0479.Cartwright M.S., Demar S., Griffin L.P., et al. Validity and reliability of nerve and muscle ultrasound. Muscle Nerve. 2013; 47(4): 515–21. doi: 10.1002/mus.23621.Cartwright M.S., Demar S., Griffin L.P., et al. Validity and reliability of nerve and muscle ultrasound. Muscle Nerve. 2013; 47(4): 515–21. doi: 10.1002/mus.23621.Arts I.M., Pillen S., Schelhaas H.J. , et al. Normal values for quantitative muscle ultrasonography in adults. Muscle Nerve. 2010; 41(1): 32-41. doi: 10.1002/mus.21458.Arts I.M., Pillen S., Schelhaas H.J. , et al. Normal values for quantitative muscle ultrasonography in adults. Muscle Nerve. 2010; 41(1): 32-41. doi: 10.1002/mus.21458.Atkinson R.A., Srinivas-Shankar U., Roberts S.A., et al. Effects of testosterone on skeletal muscle architecture in intermediate-frail and frail elderly men. J. Gerontol. A. Biol. Sci. Med. Sci. 2010; 65(11): 1215–9. doi: 10.1093/gerona/glq118.Atkinson R.A., Srinivas-Shankar U., Roberts S.A., et al. Effects of testosterone on skeletal muscle architecture in intermediate-frail and frail elderly men. J. Gerontol. A. Biol. Sci. Med. Sci. 2010; 65(11): 1215–9. doi: 10.1093/gerona/glq118.Minetto M.A., Caresio C., Menapace T., et al. Ultrasound-based detection of low muscle mass for diagnosis of sarcopenia in older adults. PM&R. 2016; 8(5): 453–62. doi: 10.1016/j. pmrj.2015.09.014.Minetto M.A., Caresio C., Menapace T., et al. Ultrasound-based detection of low muscle mass for diagnosis of sarcopenia in older adults. PM&R. 2016; 8(5): 453–62. doi: 10.1016/j. pmrj.2015.09.014.Minetto M.A., Caresio C., Salvi M., et al. Ultrasound-based detection of glucocorticoid-induced impairments of muscle mass and structure in Cushing’s disease. J Endocrinol Invest. 2019; 42(7): 757-68. doi: 10.1007/s40618-018-0979-9.Minetto M.A., Caresio C., Salvi M., et al. Ultrasound-based detection of glucocorticoid-induced impairments of muscle mass and structure in Cushing’s disease. J Endocrinol Invest. 2019; 42(7): 757-68. doi: 10.1007/s40618-018-0979-9.Provan D., Stasi R., Newland A.C., et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010; 115(2): 168-86. doi: 10.1182/ blood-2009-06-225565.Provan D., Stasi R., Newland A.C., et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010; 115(2): 168-86. doi: 10.1182/ blood-2009-06-225565.Witkowski M., Witkowska M., Robak T. Autoimmune thrombocytopenia: Current treatment options in adults with a focus on novel drugs. Eur J Haematol. 2019; 103(6): 531-41. doi: 10.1111/ejh.13319.Witkowski M., Witkowska M., Robak T. Autoimmune thrombocytopenia: Current treatment options in adults with a focus on novel drugs. Eur J Haematol. 2019; 103(6): 531-41. doi: 10.1111/ejh.13319.Khan M.A., Larson E. Acute myopathy secondary to oral steroid therapy in a 49-year-old man: a case report. J Med Case Reports. 2011; 5: 82. doi: 10.1186/1752-1947-5-82.Khan M.A., Larson E. Acute myopathy secondary to oral steroid therapy in a 49-year-old man: a case report. J Med Case Reports. 2011; 5: 82. doi: 10.1186/1752-1947-5-82.Kumar S. Steroid-induced myopathy following a single oral dose of prednisolone. Neurol India. 2003; 51(4): 554-6. PMID: 14742950.Kumar S. Steroid-induced myopathy following a single oral dose of prednisolone. Neurol India. 2003; 51(4): 554-6. PMID: 14742950.Haran M., Schattner A., Kozak N., et al. Acute steroid myopathy: a highly overlooked entity. QJM. 2018; 111(5): 307-11. doi: 10.1093/ qjmed/hcy031.Haran M., Schattner A., Kozak N., et al. Acute steroid myopathy: a highly overlooked entity. QJM. 2018; 111(5): 307-11. doi: 10.1093/ qjmed/hcy031.Liu Y., Chen S., Sun Y., et al. Clinical characteristics of immune thrombocytopenia associated with autoimmune disease: A retrospective study. Medicine (Baltimore). 2016; 95(50): e5565. doi: 10.1097/MD.0000000000005565.Liu Y., Chen S., Sun Y., et al. Clinical characteristics of immune thrombocytopenia associated with autoimmune disease: A retrospective study. Medicine (Baltimore). 2016; 95(50): e5565. doi: 10.1097/MD.0000000000005565.Buchman A.L. Side effects of corticosteroid therapy. J Clin Gastroenter ol. 2001; 33(4): 289-94. doi: 10.1097/00004836200110000-00006.Buchman A.L. Side effects of corticosteroid therapy. J Clin Gastroenter ol. 2001; 33(4): 289-94. doi: 10.1097/00004836200110000-00006.

The authors declare that there are no conflicts of interest present.